Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Drotaverine→

Drotaverine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
14009-24-6
Molecular formula
C24H31NO4
Molecular weight
397.5 g/mol
Drug class
Papaverine-like smooth-muscle antispasmodicphosphodiesterase IV inhibitor
Mechanism of action
Inhibits phosphodiesterase activity, increasing intracellular cAMP and reducing calcium-dependent smooth-muscle contraction. It acts directly on smooth muscle and does not function primarily as an antimuscarinic.
Indications / reported uses
  • Symptomatic relief of smooth-muscle spasm and associated pain, including gastrointestinal, biliary, urinary and gynaecological spasm, in countries where drotaverine is authorised; indication and route are jurisdiction-specific

Sources: NLM MeSH — Drotaverine · PubMed — Drotaverine PDE4 antispasmodic pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Drotaverine Environmental Risk Assessment (ERA) (the Drotaverine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.